AegirBio announced that it will focus towards pioneering advancements in Therapeutic Drug Monitoring (TDM) through the development of a groundbreaking platform under the RadX initiative, coupled with a robust business development strategy. In line with this decision, AegirBio will continue to offer its current MagniaReader and the two TDM tests for the MagniaReader, albeit exclusively for research purposes and will thus not uphold the CE markings for the said PoC tests for infliximab (Remicade) and natalizumab (Tysabri). These resources will be dedicated to bolstering the core focus areas of the company.

AegirBio is poised to leverage this shift in strategy to spearhead the development of a platform, positioning itself at the forefront of the healthcare industry. This pivotal move underscores the company's commitment to advancing healthcare accessibility and patient-centric solutions.